The secondary vinylphosphines Ar(F)P(H)C(R)[double bond]CH(2) [2a, Ar(F) = 2,6-(CF(3))(2)C(6)H(3), R = CH(3); 2b, Ar(F) = 2,6-(CF(3))(2)C(6)H(3), R = C(6)H(5); 2c, Ar(F) = 2,4,6-(CF(3))(3)C(6)H(2), R = CH(3)] were prepared by treating the corresponding dichlorophosphine Ar(F)PCl(2) (1) with H(2)C[double bond]C(R)MgBr. In the presence of catalytic base (DBU or DABCO) the vinylphosphines (2a-c) undergo quantitative 1,3-hydrogen migration over 3 d to give stable and isolable phosphaalkenes Ar(F)P=C(R)CH(3) (3a, Ar(F) = 2,6-(CF(3))(2)C(6)H(3), R = CH(3); 3b, Ar(F) = 2,6-(CF(3))(2)C(6)H(3), R = C(6)H(5); 3c, Ar(F) = 2,4,6-(CF(3))(3)C(6)H(2), R = CH(3)). Under analogous conditions, only 90% conversion is observed in the base-catalyzed rearrangement of MesP(H)C(CH(3))[double bond]CH(2) to MesP[double bond]C(CH(3))(2). Presumably, the increase in acidity of the P-H group when electron-withdrawing groups are employed (i.e. 2a-c) favors quantitative rearrangement to the phosphaalkene tautomer (3a-c). Thus, the double-bond migration reaction is a convenient and practical method of preparing new phosphaalkenes with C-methyl substituents.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1021/ic049796j | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical consequence of the 4-week X-ray control after ESIN osteosynthesis of forearm fractures in children.
Eur J Trauma Emerg Surg
January 2025
Department of Orthopaedics and Traumatology, University Medical Center of the Johannes Gutenberg University, 55131, Mainz, Germany.
Purpose: The absence of evidence based general guidelines for radiographic follow-ups of pediatric diaphyseal forearm fractures treated with ESIN results in an arbitrary array of X-ray examinations. In most pediatric traumatology departments, an X-ray check is carried out 4 weeks after ESIN osteosynthesis of forearm shaft fractures to detect incipient consolidation of the fracture. However, the elevated sensitivity to ionizing radiation requires special precautions in the pediatric populations.
View Article and Find Full Text PDFUnveiling alfalfa root rot resistance genes through an integrative GWAS and transcriptome study.
BMC Plant Biol
January 2025
Institute of Animal Science, Chinese Academy of Agricultural Sciences, Beijing, 100193, China.
Background: Root rot is a major disease affecting alfalfa (Medicago sativa L.), causing significant yield losses and economic damage. The primary pathogens include Fusarium spp.
View Article and Find Full Text PDFReflections on the pigments of life.
Nat Rev Chem
January 2025
Department of Chemistry, University of British Columbia, Vancouver, British Columbia, Canada.
RNA splicing variants of the novel long non-coding RNA, CyKILR, possess divergent biological functions in non-small cell lung cancer.
Mol Ther Nucleic Acids
March 2025
Department of Medicine, Division of Hematology & Oncology, University of Virginia, Charlottesville, VA 22903, USA.
The CDKN2A gene, responsible for encoding the tumor suppressors p16(INK4A) and p14(ARF), is frequently inactivated in non-small cell lung cancer (NSCLC). Herein, an uncharacterized long non-coding RNA (lncRNA) (ENSG00000267053) on chromosome 19p13.12 was found to be overexpressed in NSCLC cells with an active, wild-type CDKN2A gene.
View Article and Find Full Text PDFAnti-amyloid therapy and cerebral blood flow changes on Magnetic Resonance Imaging: a potential longitudinal biomarker of treatment response?
AJNR Am J Neuroradiol
January 2025
From the Department of Department of Radiology, Brain Health Imaging Institute (A.R-F, J.I, S.P, M.d, G.C.C) Weill Cornell Medicine, New York-Presbyterian Hospital, New York, New York, USA; the Department of Neurology (A.R-F), Pontificia Universidad Javeriana, Bogota, Colombia; the Department of Radiology, Division of Molecular Imaging and Therapeutics (A.R-F, J.I) Weill Cornell Medicine, New York-Presbyterian Hospital, New York, New York, USA; the Department of Neurology (D.Z, MM, L.R, A.S.N) Weill Cornell Medicine, New York-Presbyterian Hospital, New York, New York, USA.
Amyloid-targeting therapy has recently become widely available in the U.S. for the treatment of patients with symptomatic mild Alzheimer's disease (AD).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!